News Releases

SOUTH SAN FRANCISCO, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced the acceptance of a presentation

Trial to Evaluate TPST-1120/atezolizumab/bevacizumab triplet compared to atezolizumab/bevacizumab alone SOUTH SAN FRANCISCO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics

• Russell Vance, PhD joins Tempest Advisory Board SOUTH SAN FRANCISCO, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated

SOUTH SAN FRANCISCO, Calif. , Sept. 09, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced that management will present at

Closed merger transaction resulting in public listing (TPST) Closed $30M PIPE, extending runway into Q1’23 Advancing TPST-1495 and TPST-1120 into targeted patient populations Advanced TREX-1 program to potent lead series with in vivo efficacy SOUTH SAN FRANCISCO, Calif., Aug.

SOUTH SAN FRANCISCO, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced the appointment of

SOUTH SAN FRANCISCO, Calif., July 09, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced that Sam Whiting, M.D., Ph.D.,

SOUTH SAN FRANCISCO , July 01, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced the appointment of 20-year

SOUTH SAN FRANCISCO, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, announced today the closing of its

South San Francisco, CA, and Ann Arbor, Mich.  June 22, 2021 –Tempest Therapeutics, Inc. (“Tempest”), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, and Millendo Therapeutics, Inc. (Nasdaq: MLND) (“Millendo”), announced today the results for the proposals voted upon by Millendo stockholders at a Special Meeting on June 22, 2021. The stockholders voted in favor of all proposals at the Special Meeting, including to approve the proposed merger between the companies.

Tempest Therapeutics to Present at the Jefferies Healthcare Conference South San Francisco, CA – May 27, 2021 - Tempest Therapeutics, Inc., a clinical-stage oncology company developing first-in-class therapeutics that combine both precision and immune-mediated mechanisms, today

Tempest and Millendo Announce Proposed Merger Agreement  – Transaction to advance Tempest’s targeted oncology pipeline – Concurrent $30M PIPE financing expected to close with merger – Companies to host conference call today at 8:30 a.m.

March 8, 2021 Tempest Therapeutics to Present at the Solebury Trout/Credit Suisse/Cooley Private Company Showcase  South San Francisco, CA – March 8, 2021 - Tempest Therapeutics, Inc., a clinical-stage oncology company developing first-in-class therapeutics that combine both precision and

Tempest Therapeutics Announces Clinical Collaboration with Roche to Advance TPST-1120 into a Randomized Combination Study in First-line Hepatocellular Carcinoma   – TPST-1120/atezolizumab/bevacizumab triplet will be compared to atezolizumab/bevacizumab alone South San Francisco, CA –

Tempest Therapeutics to Present at the H.C. Wainwright Virtual Bioconnect Conference South San Francisco, CA – January 8, 2021  - Tempest Therapeutics, Inc., a clinical-stage oncology company developing first-in-class therapeutics that combine both precision and immune-mediated

Tempest Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference South San Francisco, CA – January 7, 2021 - Tempest Therapeutics, Inc., a clinical-stage oncology company developing first-in-class therapeutics that combine both precision and immune-mediated